Health Condition 1: C342- Malignant neoplasm of middle lobe,bronchus or lung Health Condition 2: C348- Malignant neoplasm of overlappingsites of bronchus and lung
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations 2. Adult male or female (18 years old or according to age of majority as defined by local regulations) 3. First ever diagnosis of lung cancer (absence of previous diagnosis of lung cancer, including small cell lung cancer [SCLC] and NSCLC) in the patientââ?¬•s medical records 4. Primary diagnosis of stage III NSCLC, confirmed by pathology, between 01 January 2013 and 31 December 2017 5. Available medical records at the participating site reflect at least 9 months of follow-up from the index date (unless patient died within the first 9 months of diagnosis)
Exclusion criteria
Exclusion criteria: 1. Patients with a concomitant cancer at the time of diagnosis of stage III NSCLC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms. A cancer will be considered concomitant if it occurs within 5 years of NSCLC diagnosis 2. Patients initially diagnosed with stage I-II NSCLC who have progressed to stage III
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS) The length of time from stage III NSCLC diagnosis (index date) or time of therapy initiation to death due to any cause.Timepoint: 9 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS)The length of time from time of therapy initiation to documented disease progression (as available in the medical record) or death due to any cause, whichever occurs first.Timepoint: 9 months | — |
Countries
Australia, Egypt, India, Indonesia, Malaysia, Singapore
Contacts
Public ContactAmit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed